ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2021

Abstract Number: 0739

Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)

Uta Kiltz1, Eerik Ahomaa2, Björn Buehring1, Xenofon Baraliakos1, David Kiefer1, Jaclyn-Dalisay Leicht1 and Jürgen Braun1, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2St. Franziskus-Hospital, Department of Orthopedic Surgery, Cologne, Germany

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2021

Keywords: axial spondyloarthritis, Environmental factors, Outcome measures, Patient reported outcomes, physical function

Session Information

Date: Sunday, November 7, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Functioning of axSpA patients (pat.) is influenced by many factors, but how contextual factors influence functioning isn’t well studied. According to the International Classification of Functioning, Disability and Health (ICF), functioning is a complex interaction between health status and contextual factors such as social support, relationships and attitudes. Resulting from impaired functioning, pat. reporting barriers might face definite limitations in participation. Thus, limitations in participation as well as barriers and facilitators of contextual factors need to be investigated in axSpA pat.

Methods: axSpA pat. were standardized assessed, thereby collecting pat. and disease characteristics, patient-reported outcomes (ASDAS, BASFI, BASMI, PHQ-9, ICF Measure of Participation and ACTivities questionnaire (IMPACT-S (0-100%)), ASAS Health Index (ASAS HI and environment factor item set (EFIS) (1). The EFIS contains 9 dichotomous questions addressing ICF categories of products and technologies (e1), support and relationship (e3), attitudes (e4) and health services (e5). Prior to the analysis, EFIS 1, 4 and 8 were assumed to act as facilitators. Validated cut-offs of ASAS HI were used to categorize global functioning: good ≤ 5, moderate < 5 to < 12, poor ≥ 12.

Results: A total of 200 axSpA pat. were included: 69% males, 44.3±12.5 years, symptom duration 17.9±12.6 years, ASDAS 2.5±1.1, BASFI 4.0±2.7, BASMI 3.5±1.8, ASAS HI 7.0±4.1. Pat. reported limitations in the IMPACT-S activity and participation domain (82.3% (15.2) and 83.5% (16.8)), respectively. The majority of pat. reported that treatment of axSpA requires time (e4, 58.5%) as a barrier. Some pat. reported needs such as (a) the support by family members (e3, 43.5%), (b) to modify home and work environment (e1, 39.5%) and (c) the inreliability of family members for help (e3, 22%) as barriers. Some pat. (< 20%) reported (a) comprehension problems with health care professionals when experiencing a flare (e5, 18.5%), (b) inadequate care of pat. at home (e4, 18.5%), (c) disliking friends' behavior toward them (e4, 13.5%), and (d) too demanding friends (e4, 13%) as barriers. The majority of pat. (e4, 75.9%) identified attitudes of friends as the only and major facilitator. All pat. reporting at least one barrier, had significantly worse global functioning (ASAS HI, IMPACT-S), and depression (PHQ-9) compared to pat. reporting no barriers in the respective ICF categories (p< 0.01). Similarly, pat. with poor functioning are more likely to report barriers in contextual factors compared to pat. with good functioning (Table 1). Pat., who have to ask for more support from their families, expressed the feeling that they cannot rely on that.

Conclusion: Barriers of contextual factors are more present in axSpA pat. than facilitators. This study shows that barriers of contextual factors are more common in pat. with impairments in self-reported and performed functioning as in those without impairments, underlining the importance of contextual factors in the management of axSpA pat. The controversial response to EF-Items 1, 4 and 8 suggests relevant differences in the individual interpretation of these questions.

Table title (on top of table): Table 1: Presence of contextual factors, stratified for global functioning categories

Table legend (below table): values given as number (%), Reference: 1 Kiltz et al. Ann Rheum Dis 2013;72(s3):572


Disclosures: U. Kiltz, AbbVie, 2, 5, 6, Biocad, 2, 6, Eli Lilly, 2, 6, Grünenthal, 2, 6, Janssen, 2, 6, MSD, 2, 6, Amgen, 5, Biogen, 5, Fresenius, 5, GlaxoSmithKline, 5, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 6, UCB, 2, 6, Hexal, 2, 5, Chugai, 2, 5; E. Ahomaa, None; B. Buehring, None; X. Baraliakos, AbbVie, 2, 5, 6, Chugai, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 5, 6, Bristol-Myers Squibb, 2, 5, 6, Celegene, 2, 5, 6, Merck, 2, 6, Werfen, 2; D. Kiefer, None; J. Leicht, None; J. Braun, Abbvie, 2, 5, 6, Amgen, 2, 5, 6, Celltrion, 2, 5, 6, Chugai, 2, 5, 6, Medac, 2, 5, 6, MSD, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 5, 6, UCB, 2, 5, 6, BMS, 2, 5, 6, Boehringer, 2, 5, 6, Celgene, 2, 5, 6, Centocor, 2, 5, 6, Mundipharma, 2, 5, 6, Sanofi-Aventis, 2, 5, 6, Eli Lilly, 2, 5, 6, EBEWE Pharma, 2, 6.

To cite this abstract in AMA style:

Kiltz U, Ahomaa E, Buehring B, Baraliakos X, Kiefer D, Leicht J, Braun J. Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/contextual-factors-should-complete-the-assessment-of-functioning-in-patients-with-axial-spondyloarthritis-axspa/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/contextual-factors-should-complete-the-assessment-of-functioning-in-patients-with-axial-spondyloarthritis-axspa/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology